SomnoMed Limited
SOMNF
$0.4361
-$0.0487-10.05%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.04% | 21.82% | 5.16% | 2.57% | 11.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.04% | 21.82% | 5.16% | 2.57% | 11.87% |
| Cost of Revenue | 20.90% | 23.72% | 13.65% | 10.85% | 14.20% |
| Gross Profit | 17.90% | 20.66% | -0.20% | -2.66% | 10.50% |
| SG&A Expenses | -3.16% | -0.90% | 8.17% | 5.50% | 18.21% |
| Depreciation & Amortization | 1.01% | 3.38% | 2.79% | 0.27% | 21.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.35% | 7.81% | 9.89% | 7.18% | 17.00% |
| Operating Income | 131.29% | 132.02% | -144.89% | -138.86% | -115.78% |
| Income Before Tax | 127.15% | 127.79% | -35.61% | -32.26% | -90.77% |
| Income Tax Expenses | 101.19% | 105.87% | 11,300.00% | 11,280.00% | -3.58% |
| Earnings from Continuing Operations | 98.34% | 98.30% | -39.69% | -36.24% | -69.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.34% | 98.30% | -36.69% | -33.32% | -67.94% |
| EBIT | 131.29% | 132.02% | -144.89% | -138.86% | -115.78% |
| EBITDA | 206.55% | 209.03% | -152.16% | -145.89% | -234.70% |
| EPS Basic | 99.10% | 99.10% | 27.62% | 29.19% | -40.76% |
| Normalized Basic EPS | 112.40% | 112.40% | 27.93% | 29.20% | -61.33% |
| EPS Diluted | 99.10% | 99.10% | 27.62% | 29.19% | -40.76% |
| Normalized Diluted EPS | 112.40% | 112.40% | 27.93% | 29.20% | -61.33% |
| Average Basic Shares Outstanding | 125.80% | 125.80% | 88.21% | 88.21% | 19.07% |
| Average Diluted Shares Outstanding | 125.80% | 125.80% | 88.21% | 88.21% | 19.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |